R&E tax credits
Plan to make permanent the current tax credits for research and experimentation expenditures is under consideration by the Senate Finance Committee for inclusion in the budget reconciliation package. The House passed a provision making the tax credit permanent on Oct. 5 in its Omnibus Budget Reconciliation bill, HR 3299. The House plan would restructure the tax credit by changing the definition of "spending base" by indexing it to individual company sales; the Finance Committee is considering a similar approach. The House also agreed to provide a permanent rule under which companies would allocate 64% of expenses for R&E conducted outside the U.S. to foreign source income.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.